Faculty
Rita S. Wickham, PhD, MS, RN, AOCN
Oncology and Palliative Care Consultant
Associate Professor
College of Nursing
Rush University Medical Center
Chicago, Illinois

Harry Raftopoulos, MD
Associate Attending Physician
Monter Cancer Center
North Shore-LIJ Health System
Lake Success, New York
 

Intended Audience
This activity is intended for nurses, physicians, and pharmacists who care for patients receiving chemotherapy as part of their therapeutic regimen and other health care professionals interested in chemotherapy-induced nausea and vomiting (CINV).

Overall Purpose

The overall purpose of this activity is to

• Familiarize oncology practitioners with best-practice recommendations

• Build value for the need to routinely assess patients for risk of CINV

• Facilitate the establishment of protocols that integrate national guidelines and standards of care for
  prevention of CINV

• Aid in the development of comprehensive patient care plans

• Effectively improve the overall quality of life for patients

Learning Objectives

After completing the educational activity, the learner should become competent to highly competent in

• Distinguishing among acute, delayed, and anticipatory CINV

• Describing best-practice recommendations for prophylaxis and treatment of CINV

• Routinely assessing patients for risk of CINV

• Establishing protocols that integrate evidence-based practice

• Developing comprehensive patient care plans

Continuing Education
Statement of Credit—Participants who successfully complete this activity (including completion and submission of the evaluation form) will be issued a statement of credit via e-mail or US mail within 4 weeks.

Physicians. The Meniscus Educational Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Meniscus Educational Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses. This activity for 1.4 contact hours is provided by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center’s Commission on Accreditation of any product mentioned. Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 1.4 contact hours.

Pharmacists. This educational activity is sponsored by the Meniscus Educational Institute. The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Program Number assigned to this program, for 1.5 contact hour(s) (0.150 CEU), is 429-000-08-006-H01-P.

ANCC Accreditation Feedback Line

1-866-262-9730

The Accreditation Program of the American Nurses Credentialing Center is interested in the opinions and perspectives of the participants in accredited continuing nursing education activities, particularly perspectives related to the presence of perceived bias* in an activity. For this reason, we provide a toll-free telephone number, which participants may call at any time to tell us about

•  Any noted bias or conflict of interest in the education

• Any concerns, compliments, or opinions

• A great experience

• An unpleasant experience

• Your thoughts on the process

Just call and tell us!

1-866-262-9730

*Bias is defined as preferential influence that causes a distortion of opinion or facts. Commercial bias may occur when an educational activity promotes one or more product(s) (drugs, devices, services, software, hardware, etc). This definition is not all inclusive, and participants may use their own interpretation in deciding wheather a presentation is biased.

NOTE: statements of commercial support and/or conflict of interest disclosures do not represent bias. Such statements inform the learner that the provider has implemented a mechanism to identify and resolve all conflicts of interest prior to delivery of the educational material.

Financial Disclosures

All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity. All faculty have been offered a modest honorarium from the accredited provider for their participation in this activity.

Rita S. Wickham, PhD, MS, RN, AOCN, Moderator, has nothing to disclose.

Harry Raftopoulos, MD, Speaker, receives honoraria from Lilly, Genentech, and Merck and receives grant or research funding from Pfizer.

Beth Taubes, RN, OCN, Nursing Education Committee Reviewer, acts as a consultant or has an advisory role for ImClone Systems, Lilly, Amgen, and Pfizer.

Barbara Conley, MD, Medical Education Committee Reviewer, receives grant or research funding from ImClone Systems, Amgen, Endocyte, Novartis, sanofi-aventis, and Wyeth.

Barry R. Goldspiel, PharmD, Pharmacy Education Committee Reviewer, has nothing to disclose.

Karen J. Abbas, RN, MS, AOCN, Nursing Education Director, has nothing to disclose.

Letitia A. O’Kicki, MD, Medical Director, has nothing to disclose.

Harleigh E. Willmott, PhD, VP, Educational Programming & Development, has nothing to disclose.